UBS Group Reiterates €108.00 Price Target for Merck KGaA (MRK)
Merck KGaA (FRA:MRK) received a €108.00 ($125.58) price target from equities research analysts at UBS Group in a note issued to investors on Tuesday, Borsen Zeitung reports. The firm currently has a “neutral” rating on the healthcare company’s stock. UBS Group’s price objective suggests a potential upside of 8.32% from the company’s current price.
MRK has been the subject of several other reports. Credit Suisse Group set a €110.00 ($127.91) target price on shares of Merck KGaA and gave the stock a “buy” rating in a research report on Friday, March 8th. Kepler Capital Markets set a €108.00 ($125.58) target price on shares of Merck KGaA and gave the stock a “buy” rating in a research report on Wednesday, February 6th. Barclays set a €82.00 ($95.35) target price on shares of Merck KGaA and gave the stock a “sell” rating in a research report on Monday. Warburg Research set a €103.00 ($119.77) target price on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Wednesday, March 20th. Finally, Independent Research set a €100.00 ($116.28) target price on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Friday, March 1st. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of €100.85 ($117.27).
MRK opened at €99.70 ($115.93) on Tuesday. Merck KGaA has a one year low of €76.60 ($89.07) and a one year high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Further Reading: What is the NASDAQ Stock Market?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.